Brief: Geneuro Receives EUR 6.4 Million In Funding From Swiss Government For Development Of Temelimab Against Long-Covid

Geneuro SA

13/12/2021 07:33

Dec 13 (Reuters) - Geneuro SA  GNRO.PA :
    * GENEURO RECEIVES CHF 6.7 MILLION (EUR 6.4 MILLION) IN
FUNDING
FROM THE SWISS GOVERNMENT FOR THE DEVELOPMENT OF TEMELIMAB
AGAINST LONG-COVID
    * SELECTION OF GENEURO'S PROJECT WITHIN FRAMEWORK OF SWISS
"FEDERAL FUNDING PROGRAMME FOR COVID-19 MEDICINES" TO FUND
CLINICAL RESEARCH INTO DRUGS FOR COVID-19
    * GOVERNMENT FUNDING OF CHF 6.7 MILLION TO SUPPORT A PHASE 2
CLINICAL TRIAL WITH TEMELIMAB IN PATIENTS SUFFERING FROM LONG-
COVID WITH NEUROLOGICAL AND PSYCHIATRIC SYMPTOMS
    * FINAL PHASE II RESULTS IN MULTIPLE SCLEROSIS EXPECTED IN
MARCH
2022

Source text for Eikon:  ID:nBwbzXbzza 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))